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Is sputum evaluation useful
for patients with community-
acquired pneumonia? 
■ EVIDENCE-BASED ANSWER
No high-quality studies specifically address the
utility of sputum Gram stain or culture in the
assessment or treatment of community-acquired
pneumonia (CAP) or nursing home–acquired
pneumonia (NHAP). The available evidence sug-
gests that analysis of the sputum adds little to
the care or outcomes of patients with CAP
(strength of recommendation [SOR]: B, inconsis-
tent results from non-randomized case control,
case series, and a systematic review of disease-
oriented evidence).
■ EVIDENCE SUMMARY
Studies investigating the role of sputum Gram
stain and culture are both difficult to interpret and
compare. The difficulty in obtaining an adequate
sputum sample, variation in preparation, levels of
skill in interpretation, and the lack of a gold stan-
dard for the microbiologic diagnosis of pneumonia
all contribute to these difficulties.1
The sole meta-analysis identified 12 studies
that met 17 specified study criteria regarding the
use of sputum Gram stain for patients with com-
munity-acquired pneumococcal pneumonia.1
Sample sizes ranged from 16 to 404; reference
standards were most frequently sputum culture
but also included culture of transtracheal and
bronchial aspirates. Results revealed that
patients with community-acquired pneumococcal
pneumonia were able to produce a valid sputum
sample (>20 neutrophils, <10 squamous epithe-
lial cells per low-power field) 70% of the time; the
sensitivity of sputum Gram stain ranged from
15% to 69% (when reviewed by a lab technician);
and specificity ranged from 11% to 100%. 
Because of the heterogeneity of test characteris-
tics, interpreter skill levels, study populations, and
reference standards among the studies in this
meta-analysis, no single estimate of Gram stain
sensitivity or specificity could be reached. Similarly,
information regarding the sensitivity and specifici-
ty of sputum culture is lacking. Small studies
(n=13–85) using blood culture, transthoracic aspi-
rate, or transtracheal aspirate as reference stan-
dards in untreated cases of definite pneumococcal
pneumonia demonstrate sensitivities ranging from
36% to 100%.2 There are no reliable data regarding
the specificity of sputum culture.
Recent nonrandomized studies and case series
have called into question the role of sputum analy-
sis in CAP. In a case-control study of 605 patients
hospitalized with CAP diagnosed by chest x-ray and
either cough, chest pain, auscultatory findings, or
leukocytosis, establishing an etiologic diagnosis did
not influence the choice of antibiotic therapy, length
of hospital stay, or mortality.3 Of the 482 patients
who had microbiological diagnostics performed
(Mycoplasma pneumoniae serology, respiratory virus
serology, blood culture, or sputum culture), only
132 (27%) had a presumptive etiologic diagnosis
made. Therapy was narrowed or focused in 49 of
the 132 (37%) patients who had a presumptive eti-
ologic diagnosis, while 84 of the 350 (24%) without
a presumptive diagnosis had their therapy nar-
rowed (P>.05). There was no difference in in-hospi-
tal changes of therapy, the proportion of new regi-
mens having a narrower antimicrobial spectrum
than the initial one, length of hospital stay, death in
hospital, or death within 3 months after admission. 
A prospective study of 74 patients suggested
sputum studies had little use in a highly selected
population aged <65 years with nonsevere,
uncomplicated CAP and no comorbidities. In the
74 patients who produced a valid sputum sample,
Gram stain failed to identify the causative agent in
any patient (sensitivity 0%), and sputum cultures
identified a pathogen in only 4 patients (sensitivi-
ty 5%). All patients responded similarly and, even
with the identification of a pathogen in 4 patients,
there were no changes in initial empiric antibi-
otics.4 In a retrospective case series, 19 of 54
(35%) patients with SCAP did not respond to ini-
tial empiric antibiotics and had a change in their
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antibiotic regimen. There was no difference in
mortality between the group that had empiric
antibiotic change (11 patients) and the group that
had a change based on sputum culture results (3
patients) (relative risk reduction= –0.14; 95%
confidence interval, –0.47 to 0.12).5 While these
studies suggest the need for re-evaluation of rou-
tine sputum analysis, the strength of their con-
clusions are weakened by lack of randomization,
small sample size, inadequate blinding, and lack
of control group comparison. 
Demographic evidence and nonrandomized tri-
als suggest that patients with CAP who have
increased risk of infection from multiple-resistant
bacteria, such as patients from long-term care
facilities, are a unique population that might need
to be evaluated differently. However, the only evi-
dence available regarding the utility of either spu-
tum Gram stain or culture for patients with
NHAP derives from expert opinion. These
authors suggest that determining a causative
diagnosis of pneumonia in this population is
desirable and postulate that sputum examination
would permit recognition of multiply resistant
organisms that are being isolated with increasing
frequency in long-term care facilities.6,7 However,
the same authors acknowledge that the elderly
are often too weak or too confused to provide ade-
quate sputum specimens, resulting in a low diag-
nostic yield, and no data demonstrate that spu-
tum evaluation favorably influences the outcome
of pneumonia in these patient populations.
■ RECOMMENDATIONS FROM OTHERS
The Infectious Disease Society of America
(IDSA) and the Canadian Infectious Disease
Society/Canadian Thoracic Society (CIDS/CTS)
recommend routine sputum analysis for all inpa-
tients with CAP or NHAP,8,9 while the American
Thoracic Society (ATS)10 recommends performing
sputum analysis only if a drug-resistant pathogen
or an organism not covered by usual empiric ther-
apy is suspected. For those with CAP or NHAP
treated as outpatients, the ATS, the IDSA, and
the CIDS/CTS recommend microbiological testing
only if drug-resistant bacteria or an organism not
covered by usual empiric therapy is suspected. 
Carl G. Morris, MD, Department of Family Medicine,
University of Washington; Sarah Safranek, MLIS,
University of Washington Health Sciences Libraries
■ CLINICAL COMMENTARY
In the outpatient setting, a search 
for the cause is not likely to be helpful
We are fortunate to have excellent guidelines
for the empiric treatment of pneumonia
because it is difficult to identify the causative
organism. There remain, however, theoretical
benefits to uncovering the cause: identification
of rare organisms, selection of narrower spec-
trum antibiotics (lessening the community bur-
den of antibiotic resistance), and better target-
ing of medications should empiric therapy
prove ineffective. In the outpatient setting, a
search for the cause is not likely to be helpful.
In the inpatient setting—particularly in situa-
tions where empiric therapy is failing—desper-
ation is a powerful motivator and still prompts
use of all options available.
Jon Neher, MD, Valley Medical Center, Renton, Wash
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What is the best regimen 
for newly diagnosed
hypertension?
■ EVIDENCE-BASED ANSWER
Low-dose thiazide diuretics (eg, hydrochloroth-
iazide 12.5 to 25 mg/d) are the best first-line phar-
macotherapy for treating uncomplicated hyperten-
sion (strength of recommendation [SOR]: A, based
on randomized trials [RCTs] and 1 meta-analysis).
Alternate first-line agents include angiotensin-
converting enzyme (ACE) inhibitors, beta 
blockers, and calcium channel blockers (SOR: A,
based on RCTs).
■ EVIDENCE SUMMARY
Three landmark placebo-controlled studies have
established that thiazide diuretic–based treat-
ment reduces morbidity and mortality among
patients with hypertension.1–3 Based on these
data, thiazide diuretic therapy is considered 
the gold-standard treatment for uncomplicated 
hypertension.
Several other clinical trials have subsequently
compared the effect of thiazide diuretics with
that of other antihypertensive agents (beta-block-
ers, calcium channel blockers, and alpha-block-
ers) on patient-oriented outcomes. These were
analyzed in a recent meta-analysis of 42 clinical
trials that included 192,478 patients randomized
to 7 treatment strategies including placebo.4
Results from the largest antihypertensive clinical
trial, the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALL-
HAT), were included in this meta-analysis.5
Comparative results are depicted in the Table.
Although these data showed no differences
between drug therapies in total and cardiovascu-
lar disease mortality, low-dose diuretics reduced
certain cardio-vascular endpoints (ie, heart fail-
ure, stroke, cardiovascular disease events) more
than other drug therapies. 
Angiotensin receptor blockers (ARBs) have
not been compared with thiazide diuretics in a
trial. Two long-term trials have compared an ARB
to other types of drug therapy: losartan vs
atenolol in the Losartan Intervention for
Endpoint Reduction (LIFE) trial,6 and valsartan
vs amlodipine in the Valsartan Antihypertensive
Long-term Use Evaluation (VALUE) trial.7 In the
LIFE trial, the primary composite endpoint of car-
diovascular death, myocardial infarction, and
stroke was less with losartan than atenolol (23.8
vs 27.9 events per 1000 patient-years, losartan
and atenolol, respectively; number needed to
treat=243 people-years, P=.021).6 However, in
the VALUE trial, the primary endpoint of time to
cardiac event was not different between valsar-
tan and amlodipine (25.5 vs 24.7 events per 1000
patient-years, valsartan and amlodipine, respec-
tively; P=.49).7
■ RECOMMENDATIONS FROM OTHERS
The Seventh Report of the Joint National
Committee (JNC7) recommended thiazide diuret-
ics as preferred initial agents in uncomplicated
hypertension.8 The European Society of Hyper-
tension/European Society Cardiology recom-
mended either a diuretic, beta-blocker, calcium
channel blocker, ACE inhibitor, or ARB for initial
therapy stating that blood pressure control to rec-
ommended values via any agent is more impor-
tant than the type of agent used.9 Both guidelines
identified other antihypertensives that may be
used in addition to or in place of thiazide diuret-
ics for compelling indications, such as heart fail-
ure, diabetes, high-risk cardiovascular disease,
chronic kidney disease, post-myocardial infarc-
tion, and secondary stroke prevention.
